Cancer | pharmaphorum

Skip to main content

Saturday 20 June 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Cancer

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

UK and US spearhead search for drugs targeting RAS mutations

Cancer Research UK and its Cancer Research Technology Pioneer Fund have joined with the US National Cancer Institute (NCI) to test new molecules targeting RAS mutations.

News

AbbVie-HQ

Doubts over AbbVie PARP inhibitor after double trial failure

Veliparib fails in two phase 3 trials.

News

nasdaq

Are biotech IPOs back in fashion?

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public.

News

novartis-campus-basel

Novartis and Allergan to combine drugs in NASH

Swiss pharma also aims for new CAR-T therapy indication.

News

gottlieb_hearing

Gottlieb grilled by Senators over industry links

But Trump's nomination for FDA chief keeps calm under pressure.

News

Boehringer Ingelheim Center (BIC)

Boehringer looks to cancer immunotherapy combinations

BI developing combinations with its own checkpoint inhibitors

Load more results

Editor's Picks

UK approves Novo Nordisk's Wegovy pill

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

Patient information exposed in breach, says Novo Nordisk

Cancer biotech Parabilis books record IPO, raising $670m

UK offers meningitis jab to young people after outbreak

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company